{
    "hands_on_practices": [
        {
            "introduction": "The first step in applying pharmacogenomics clinically is to translate a patient's genetic information, or diplotype, into a predicted functional phenotype. A common and effective method is to construct an activity score model, where alleles are assigned weights based on their known function, and these weights are summed to predict an individual's total enzyme capacity. This practice  develops this foundational skill by guiding you through the creation of a simple additive model to classify UGT1A1 diplotypes into clinically meaningful categories such as normal, intermediate, and poor metabolizers.",
            "id": "4573033",
            "problem": "A central objective in clinical pharmacology is to rationally translate genotype into predicted enzyme activity to inform dosing. For the glucuronidation pathway catalyzed by UDP-glucuronosyltransferase family 1 member A1 (UGT1A1), consider the following mechanistic premises grounded in biochemistry and pharmacogenomics:\n\n1. Under conditions where substrate concentrations are comparable across individuals and the Michaelis–Menten constant is unaffected by genotype, the initial reaction velocity $v$ is proportional to the maximal velocity $V_{\\max}$, and $V_{\\max}$ is proportional to the active enzyme concentration $[E]$. Thus, predicted catalytic capacity is proportional to $[E]$.\n\n2. In a diploid genome, the total active enzyme concentration $[E]$ is the sum of contributions from the two alleles, assuming no dominant-negative interactions or compensatory regulation, i.e., $[E] \\propto a_{1} + a_{2}$, where $a_{i}$ is the per-allele activity contribution.\n\n3. The reference allele *UGT1A1\\*1* is a normal function allele, while *UGT1A1\\*28* is a decreased function allele due to promoter thymine–adenine repeat expansion that lowers transcription efficiency. For the purpose of constructing a quantitative activity score, assign per-allele activity weights $w_{N} = 1.0$ for normal function and $w_{D} = 0.5$ for decreased function.\n\n4. Normalize the diplotype activity score $S$ to be the sum of the two per-allele weights, so that the maximum possible score is $S_{\\max} = 2.0$. Define phenotype bins by relative capacity cutpoints anchored to clinically meaningful fractions of $S_{\\max}$: poor metabolizer if $S \\leq 1.0$, intermediate metabolizer if $1.0 < S < 1.5$, and normal metabolizer if $S \\geq 1.5$.\n\nTasks:\n- Using only the premises above and first-principles reasoning about additivity of allele contributions to enzyme concentration, construct the activity score model and compute the activity scores $S$ for the UGT1A1 diplotypes *UGT1A1\\*1*/*UGT1A1\\*1*, *UGT1A1\\*1*/*UGT1A1\\*28*, and *UGT1A1\\*28*/*UGT1A1\\*28*.\n- Determine the phenotype category for each diplotype according to the cutpoints provided. For reporting compactness, internally encode phenotype as a numeric code: poor metabolizer $= 0$, intermediate metabolizer $= 1$, normal metabolizer $= 2$.\n- For the final boxed answer, report only a single row matrix containing, in order, the three activity scores $S$ for *UGT1A1\\*1*/*UGT1A1\\*1*, *UGT1A1\\*1*/*UGT1A1\\*28*, and *UGT1A1\\*28*/*UGT1A1\\*28*. Do not include phenotype codes in the final boxed answer.\n\nNo rounding is required; report exact values. No units are to be provided, as the scores are unitless.",
            "solution": "The problem statement is evaluated as scientifically grounded, well-posed, and objective. It provides a clear, self-contained model for translating genetic information (diplotypes) into a quantitative activity score and a categorical phenotype. All premises are consistent and sufficient for arriving at a unique solution. The model, while a simplification of complex biological reality, is a standard and valid heuristic used in the field of pharmacogenomics. Therefore, a solution is warranted.\n\nThe core of the problem is to construct and apply a quantitative activity score model based on the provided premises.\n\nPremise 1 establishes a direct proportionality between initial reaction velocity $v$ and the total active enzyme concentration $[E]$, such that catalytic capacity $\\propto [E]$.\nPremise 2 posits an additive model for the total enzyme concentration based on contributions from each of the two alleles in a diploid genome: $[E] \\propto a_{1} + a_{2}$, where $a_i$ is the activity contribution from allele $i$.\nCombining these, the catalytic capacity is proportional to the sum of the per-allele contributions.\n\nPremise 3 assigns quantitative weights to the per-allele contributions. Let $w_{\\text{allele}}$ be the activity weight for a given allele.\nFor the normal function allele *UGT1A1\\*1*, the weight is $w_{N} = 1.0$.\nFor the decreased function allele *UGT1A1\\*28*, the weight is $w_{D} = 0.5$.\n\nPremise 4 defines the diplotype activity score, $S$, as the sum of the weights of the two alleles present in the diplotype. For a diplotype composed of allele $A$ and allele $B$, the score is given by the model:\n$$S = w_{A} + w_{B}$$\n\nUsing this model, we will compute the activity scores for the three specified diplotypes.\n\n1.  ** *UGT1A1\\*1*/*UGT1A1\\*1* (homozygous normal/wild-type):**\n    This individual has two copies of the *UGT1A1\\*1* allele. The activity score, which we denote as $S_{1/1}$, is the sum of the weights for each of these two alleles.\n    $$S_{1/1} = w_{\\text{UGT1A1*1}} + w_{\\text{UGT1A1*1}} = w_{N} + w_{N} = 1.0 + 1.0 = 2.0$$\n\n2.  ** *UGT1A1\\*1*/*UGT1A1\\*28* (heterozygous):**\n    This individual has one copy of the *UGT1A1\\*1* allele and one copy of the *UGT1A1\\*28* allele. The activity score, $S_{1/28}$, is the sum of their respective weights.\n    $$S_{1/28} = w_{\\text{UGT1A1*1}} + w_{\\text{UGT1A1*28}} = w_{N} + w_{D} = 1.0 + 0.5 = 1.5$$\n\n3.  ** *UGT1A1\\*28*/*UGT1A1\\*28* (homozygous decreased function):**\n    This individual has two copies of the *UGT1A1\\*28* allele. The activity score, $S_{28/28}$, is the sum of the weights for each of these two alleles.\n    $$S_{28/28} = w_{\\text{UGT1A1*28}} + w_{\\text{UGT1A1*28}} = w_{D} + w_{D} = 0.5 + 0.5 = 1.0$$\n\nNext, we determine the phenotype for each diplotype using the provided cutpoints and numeric codes (poor metabolizer $= 0$, intermediate metabolizer $= 1$, normal metabolizer $= 2$).\nThe phenotype bins are defined as:\n- Poor metabolizer: $S \\leq 1.0$\n- Intermediate metabolizer: $1.0 < S < 1.5$\n- Normal metabolizer: $S \\geq 1.5$\n\n-   For the *UGT1A1\\*1*/*UGT1A1\\*1* diplotype, the score is $S_{1/1} = 2.0$. Since $2.0 \\geq 1.5$, the phenotype is **normal metabolizer** (code $2$).\n\n-   For the *UGT1A1\\*1*/*UGT1A1\\*28* diplotype, the score is $S_{1/28} = 1.5$. Since $1.5 \\geq 1.5$, the phenotype is **normal metabolizer** (code $2$). The score falls on the boundary, and the definition for normal metabolizer is inclusive of $1.5$.\n\n-   For the *UGT1A1\\*28*/*UGT1A1\\*28* diplotype, the score is $S_{28/28} = 1.0$. Since $1.0 \\leq 1.0$, the phenotype is **poor metabolizer** (code $0$). The score falls on the boundary, and the definition for a poor metabolizer is inclusive of $1.0$.\n\nThe problem demands that the final answer be a row matrix containing only the three activity scores in the specified order: *UGT1A1\\*1*/*UGT1A1\\*1*, *UGT1A1\\*1*/*UGT1A1\\*28*, and *UGT1A1\\*28*/*UGT1A1\\*28*.\nThe calculated scores are $2.0$, $1.5$, and $1.0$.",
            "answer": "$$\n\\boxed{\n\\begin{pmatrix}\n2.0 & 1.5 & 1.0\n\\end{pmatrix}\n}\n$$"
        },
        {
            "introduction": "Once a patient is assigned a metabolizer phenotype, the next critical step is to understand the quantitative biochemical impact of this genetic variation. By applying the principles of Michaelis-Menten enzyme kinetics, we can directly link a genetically determined reduction in enzyme concentration—reflected as a lower maximal reaction velocity ($V_{\\max}$)—to the actual rate of drug metabolism ($v$) at a given substrate concentration. This exercise  provides a practical application of this principle, demonstrating how the reduced expression associated with a UGT1A1 variant translates into a decreased rate of SN-38 glucuronidation.",
            "id": "4573068",
            "problem": "A hepatic microsomal preparation is used to study glucuronidation of SN-38, the active metabolite of irinotecan, by uridine diphosphate (UDP)-glucuronosyltransferase 1A1 (UGT1A1). Consider two genotypes: a reference genotype with full UGT1A1 expression and a reduced-expression genotype in which enzyme expression is halved due to a promoter polymorphism, while substrate binding affinity is unchanged. Assume the elementary enzyme mechanism under initial rate conditions and the quasi-steady-state approximation:\n$$\nE + S \\xrightleftharpoons[k_{-1}]{k_{1}} ES \\xrightarrow{k_{\\mathrm{cat}}} E + P,\n$$\nwith total enzyme concentration $[E]_{T}$, and define $K_{m}$ and $V_{\\max}$ using standard enzyme kinetics.\n\nFor both genotypes, the substrate concentration is $[S]=2\\ \\mu\\mathrm{M}$ and the Michaelis constant is $K_{m}=5\\ \\mu\\mathrm{M}$. The reference genotype has $V_{\\max}=100\\ \\mathrm{nmol}\\ \\mathrm{min}^{-1}\\ \\mathrm{mg}^{-1}$, while the reduced-expression genotype has $V_{\\max}=50\\ \\mathrm{nmol}\\ \\mathrm{min}^{-1}\\ \\mathrm{mg}^{-1}$.\n\nStarting from the mechanism and definitions above, derive the expression for the initial reaction velocity $v$ as a function of $V_{\\max}$, $K_{m}$, and $[S]$. Then compute $v$ for each genotype at $[S]=2\\ \\mu\\mathrm{M}$. Round your computed velocities to four significant figures. Express $v$ in $\\mathrm{nmol}\\ \\mathrm{min}^{-1}\\ \\mathrm{mg}^{-1}$.\n\nFinally, based solely on your computed velocities and assuming comparable hepatic uptake and distribution between genotypes, briefly interpret the pharmacological consequence for systemic SN-38 exposure in the reduced-expression genotype relative to the reference genotype.",
            "solution": "The problem is subjected to validation and is deemed valid. It is scientifically grounded in the principles of enzyme kinetics and pharmacogenomics, it is well-posed with sufficient and consistent data, and it is expressed in objective, formal language. We may therefore proceed with the solution.\n\nThe problem requires the derivation of the initial reaction velocity expression, computation of the velocity for two genotypes, and a pharmacological interpretation of the results.\n\n**1. Derivation of the Initial Reaction Velocity Expression**\n\nThe enzymatic reaction is described by the following mechanism:\n$$ E + S \\xrightleftharpoons[k_{-1}]{k_{1}} ES \\xrightarrow{k_{\\mathrm{cat}}} E + P $$\nwhere $E$ is the enzyme (UGT1A1), $S$ is the substrate (SN-38), $ES$ is the enzyme-substrate complex, and $P$ is the product (SN-38 glucuronide). The rate constants for the association, dissociation, and catalytic steps are $k_1$, $k_{-1}$, and $k_{\\mathrm{cat}}$, respectively.\n\nThe rate of change of the enzyme-substrate complex concentration, $[ES]$, is given by:\n$$ \\frac{d[ES]}{dt} = k_{1}[E][S] - k_{-1}[ES] - k_{\\mathrm{cat}}[ES] = k_{1}[E][S] - (k_{-1} + k_{\\mathrm{cat}})[ES] $$\nThe problem states to assume the quasi-steady-state approximation (QSSA), which posits that the concentration of the intermediate complex $[ES]$ remains nearly constant after a very brief initial phase of the reaction. Therefore, we set its rate of change to zero:\n$$ \\frac{d[ES]}{dt} \\approx 0 $$\nThis implies that the rate of formation of $ES$ is equal to its rate of breakdown:\n$$ k_{1}[E][S] = (k_{-1} + k_{\\mathrm{cat}})[ES] $$\nThe total enzyme concentration, $[E]_T$, is the sum of the free enzyme, $[E]$, and the enzyme bound in the complex, $[ES]$:\n$$ [E]_T = [E] + [ES] $$\nFrom this conservation equation, we can express the free enzyme concentration as $[E] = [E]_T - [ES]$. Substituting this into the steady-state equation gives:\n$$ k_{1}([E]_T - [ES])[S] = (k_{-1} + k_{\\mathrm{cat}})[ES] $$\nOur goal is to solve for $[ES]$. Expanding the left side yields:\n$$ k_{1}[E]_T[S] - k_{1}[ES][S] = (k_{-1} + k_{\\mathrm{cat}})[ES] $$\nRearranging the terms to isolate $[ES]$:\n$$ k_{1}[E]_T[S] = (k_{-1} + k_{\\mathrm{cat}})[ES] + k_{1}[ES][S] $$\n$$ k_{1}[E]_T[S] = (k_{-1} + k_{\\mathrm{cat}} + k_{1}[S])[ES] $$\nSolving for $[ES]$:\n$$ [ES] = \\frac{k_{1}[E]_T[S]}{k_{-1} + k_{\\mathrm{cat}} + k_{1}[S]} $$\nTo simplify this expression, we divide the numerator and the denominator by $k_1$:\n$$ [ES] = \\frac{[E]_T[S]}{\\frac{k_{-1} + k_{\\mathrm{cat}}}{k_1} + [S]} $$\nStandard enzyme kinetics defines the Michaelis constant, $K_m$, as:\n$$ K_m = \\frac{k_{-1} + k_{\\mathrm{cat}}}{k_1} $$\nSubstituting $K_m$ into the expression for $[ES]$ yields:\n$$ [ES] = \\frac{[E]_T[S]}{K_m + [S]} $$\nThe initial reaction velocity, $v$, is the rate of product formation, which is proportional to the concentration of the $ES$ complex:\n$$ v = \\frac{d[P]}{dt} = k_{\\mathrm{cat}}[ES] $$\nSubstituting the derived expression for $[ES]$ into the velocity equation gives:\n$$ v = k_{\\mathrm{cat}} \\frac{[E]_T[S]}{K_m + [S]} = \\frac{k_{\\mathrm{cat}}[E]_T[S]}{K_m + [S]} $$\nThe maximum velocity, $V_{\\max}$, is achieved when the enzyme is fully saturated with substrate, i.e., when $[ES] = [E]_T$. In this case, $v = V_{\\max} = k_{\\mathrm{cat}}[E]_T$. Substituting this definition into the velocity equation gives the final Michaelis-Menten equation:\n$$ v = \\frac{V_{\\max}[S]}{K_m + [S]} $$\nThis is the required expression for the initial reaction velocity $v$.\n\n**2. Computation of Reaction Velocity for Each Genotype**\n\nWe will now use the derived equation to compute the initial velocity for the reference and reduced-expression genotypes at a substrate concentration of $[S] = 2\\ \\mu\\mathrm{M}$.\n\nFor both genotypes, the Michaelis constant is given as $K_m = 5\\ \\mu\\mathrm{M}$.\n\n**Reference Genotype:**\nThe maximum velocity for the reference genotype is $V_{\\max, \\text{ref}} = 100\\ \\mathrm{nmol}\\ \\mathrm{min}^{-1}\\ \\mathrm{mg}^{-1}$.\nThe initial velocity, $v_{\\text{ref}}$, is:\n$$ v_{\\text{ref}} = \\frac{V_{\\max, \\text{ref}}[S]}{K_m + [S]} = \\frac{(100\\ \\mathrm{nmol}\\ \\mathrm{min}^{-1}\\ \\mathrm{mg}^{-1})(2\\ \\mu\\mathrm{M})}{5\\ \\mu\\mathrm{M} + 2\\ \\mu\\mathrm{M}} $$\n$$ v_{\\text{ref}} = \\frac{200}{7}\\ \\mathrm{nmol}\\ \\mathrm{min}^{-1}\\ \\mathrm{mg}^{-1} \\approx 28.5714\\ \\mathrm{nmol}\\ \\mathrm{min}^{-1}\\ \\mathrm{mg}^{-1} $$\nRounding to four significant figures, the velocity for the reference genotype is:\n$$ v_{\\text{ref}} = 28.57\\ \\mathrm{nmol}\\ \\mathrm{min}^{-1}\\ \\mathrm{mg}^{-1} $$\n\n**Reduced-Expression Genotype:**\nThe maximum velocity for the reduced-expression genotype is $V_{\\max, \\text{red}} = 50\\ \\mathrm{nmol}\\ \\mathrm{min}^{-1}\\ \\mathrm{mg}^{-1}$. This is consistent with the problem statement that enzyme expression is halved, as $V_{\\max}$ is directly proportional to the total enzyme concentration $[E]_T$.\nThe initial velocity, $v_{\\text{red}}$, is:\n$$ v_{\\text{red}} = \\frac{V_{\\max, \\text{red}}[S]}{K_m + [S]} = \\frac{(50\\ \\mathrm{nmol}\\ \\mathrm{min}^{-1}\\ \\mathrm{mg}^{-1})(2\\ \\mu\\mathrm{M})}{5\\ \\mu\\mathrm{M} + 2\\ \\mu\\mathrm{M}} $$\n$$ v_{\\text{red}} = \\frac{100}{7}\\ \\mathrm{nmol}\\ \\mathrm{min}^{-1}\\ \\mathrm{mg}^{-1} \\approx 14.2857\\ \\mathrm{nmol}\\ \\mathrm{min}^{-1}\\ \\mathrm{mg}^{-1} $$\nRounding to four significant figures, the velocity for the reduced-expression genotype is:\n$$ v_{\\text{red}} = 14.29\\ \\mathrm{nmol}\\ \\mathrm{min}^{-1}\\ \\mathrm{mg}^{-1} $$\nAs expected, the calculated reaction velocity for the reduced-expression genotype is half that of the reference genotype ($14.29/28.57 \\approx 0.5$).\n\n**3. Interpretation of Pharmacological Consequence**\n\nThe calculated velocity, $v$, represents the rate of metabolic clearance of SN-38 via glucuronidation in this in vitro system. The reduced-expression genotype exhibits a metabolic rate ($v_{\\text{red}} = 14.29\\ \\mathrm{nmol}\\ \\mathrm{min}^{-1}\\ \\mathrm{mg}^{-1}$) that is half that of the reference genotype ($v_{\\text{ref}} = 28.57\\ \\mathrm{nmol}\\ \\mathrm{min}^{-1}\\ \\mathrm{mg}^{-1}$).\n\nAssuming this in vitro finding translates to in vivo pharmacology and that other factors like hepatic uptake and distribution are comparable, a reduced rate of SN-38 metabolism will lead to slower clearance of the active metabolite from the body. Consequently, patients with the reduced-expression UGT1A1 genotype will experience higher and more prolonged systemic exposure (i.e., a larger area under the concentration-time curve, AUC) to SN-38. Since SN-38 is the primary agent of both the therapeutic effect and the major dose-limiting toxicities (e.g., severe neutropenia and diarrhea) of irinotecan, this increased exposure significantly heightens the risk of severe adverse drug reactions.",
            "answer": "$$\n\\boxed{\\begin{pmatrix} 28.57 & 14.29 \\end{pmatrix}}\n$$"
        },
        {
            "introduction": "In a clinical setting, a patient's genetic makeup often interacts with other physiological or pharmacological factors, such as co-administered drugs that inhibit the same metabolic pathway. This final practice explores such a gene-drug interaction by modeling the combined effect of a UGT1A1 reduced-function genotype and a UGT1A1-inhibiting drug on bilirubin clearance. Using a fundamental pharmacokinetic relationship at steady state ($C_{\\mathrm{ss}} = R/CL$), this exercise  will allow you to quantify the cumulative impact on a clinical biomarker, illustrating how multiple factors can synergistically increase the risk of adverse effects.",
            "id": "4573078",
            "problem": "A clinician is evaluating the risk of indirect (unconjugated) hyperbilirubinemia in a patient initiating atazanavir therapy. Unconjugated bilirubin is cleared predominantly by UDP-glucuronosyltransferase 1A1 (UGT1A1). Consider a simplified one-compartment, linear mass-balance model for unconjugated bilirubin in which, at steady state, the formation rate equals the elimination rate. Let the bilirubin formation rate be constant and equal to $R$ (mass per unit time), and let the UGT1A1-mediated clearance be $CL$ (volume per unit time). The steady-state concentration is $C_{\\mathrm{ss}}$ (mass per unit volume). Assume first-order elimination, no compensatory changes in formation with enzyme inhibition, and that non-UGT1A1 elimination is negligible relative to UGT1A1 under the concentration range considered.\n\nA wild-type individual has a measured steady-state unconjugated bilirubin concentration of $0.7$ mg/dL. A different patient is homozygous for the UGT1A1*28 allele (UGT1A1*28/*28), which reduces UGT1A1-mediated clearance by $0.50$ relative to wild-type, and is starting atazanavir, which independently reduces UGT1A1-mediated clearance by an additional $0.30$ relative to the patient’s on-genotype baseline. Assume the genotype and drug effects are independent and multiplicative on $CL$.\n\nUsing the steady-state production–clearance principle and the assumptions above, compute the expected increase in the patient’s steady-state unconjugated bilirubin concentration (difference from the wild-type concentration). Round your answer to four significant figures and express it in mg/dL.",
            "solution": "The problem is evaluated to be scientifically grounded, well-posed, objective, and internally consistent. It is based on standard principles of pharmacokinetics and pharmacogenomics, providing all necessary data for a unique solution. Therefore, the problem is deemed valid and a full solution is provided below.\n\nThe core principle governing the system is the mass-balance equation at steady state, where the rate of formation of unconjugated bilirubin equals its rate of elimination. The problem states that the formation rate is a constant, denoted by $R$, and the elimination follows first-order kinetics. The rate of elimination is the product of the clearance, $CL$, and the steady-state concentration, $C_{\\mathrm{ss}}$.\n\nThus, the governing equation is:\n$$R = CL \\times C_{\\mathrm{ss}}$$\nThis equation can be rearranged to express the steady-state concentration as a function of the formation rate and clearance:\n$$C_{\\mathrm{ss}} = \\frac{R}{CL}$$\nThe problem assumes that the bilirubin formation rate $R$ is constant across all individuals. This implies that the steady-state concentration of bilirubin is inversely proportional to its clearance.\n\nLet $C_{\\mathrm{ss, WT}}$ and $CL_{\\mathrm{WT}}$ denote the steady-state concentration and clearance in a wild-type individual, respectively.\nLet $C_{\\mathrm{ss, p}}$ and $CL_{\\mathrm{p}}$ denote the steady-state concentration and clearance in the patient of interest, who has the UGT1A1*28/*28 genotype and is taking atazanavir.\n\nFrom the inverse proportionality, we can establish a relationship between the concentrations and clearances of the wild-type individual and the patient:\n$$\\frac{C_{\\mathrm{ss, p}}}{C_{\\mathrm{ss, WT}}} = \\frac{R / CL_{\\mathrm{p}}}{R / CL_{\\mathrm{WT}}} = \\frac{CL_{\\mathrm{WT}}}{CL_{\\mathrm{p}}}$$\nThis allows us to calculate $C_{\\mathrm{ss, p}}$ by determining the ratio of the clearances.\n\nNext, we calculate the patient's clearance, $CL_{\\mathrm{p}}$, relative to the wild-type clearance, $CL_{\\mathrm{WT}}$.\nThe patient's genotype, UGT1A1*28/*28, reduces clearance by $0.50$ relative to wild-type. This means the patient's clearance due to genotype alone, which we can call the on-genotype baseline clearance $CL_{\\mathrm{geno}}$, is $1 - 0.50 = 0.50$ times the wild-type clearance.\n$$CL_{\\mathrm{geno}} = (1 - 0.50) \\times CL_{\\mathrm{WT}} = 0.50 \\times CL_{\\mathrm{WT}}$$\nThe drug atazanavir causes an additional reduction in clearance of $0.30$ relative to this on-genotype baseline. Since the effects are stated to be multiplicative, the final clearance for the patient, $CL_{\\mathrm{p}}$, is:\n$$CL_{\\mathrm{p}} = (1 - 0.30) \\times CL_{\\mathrm{geno}}$$\nSubstituting the expression for $CL_{\\mathrm{geno}}$:\n$$CL_{\\mathrm{p}} = 0.70 \\times (0.50 \\times CL_{\\mathrm{WT}}) = 0.35 \\times CL_{\\mathrm{WT}}$$\nThus, the patient's total clearance is $35\\%$ of the wild-type clearance.\n\nNow we can calculate the patient's expected steady-state bilirubin concentration, $C_{\\mathrm{ss, p}}$. We are given that the wild-type concentration is $C_{\\mathrm{ss, WT}} = 0.7$ mg/dL.\n$$C_{\\mathrm{ss, p}} = C_{\\mathrm{ss, WT}} \\times \\frac{CL_{\\mathrm{WT}}}{CL_{\\mathrm{p}}} = C_{\\mathrm{ss, WT}} \\times \\frac{CL_{\\mathrm{WT}}}{0.35 \\times CL_{\\mathrm{WT}}}$$\nThe $CL_{\\mathrm{WT}}$ terms cancel, yielding:\n$$C_{\\mathrm{ss, p}} = \\frac{C_{\\mathrm{ss, WT}}}{0.35} = \\frac{0.7}{0.35} = 2.0 \\, \\text{mg/dL}$$\n\nThe problem asks for the increase in the patient's steady-state concentration relative to the wild-type concentration. Let this increase be $\\Delta C_{\\mathrm{ss}}$.\n$$\\Delta C_{\\mathrm{ss}} = C_{\\mathrm{ss, p}} - C_{\\mathrm{ss, WT}}$$\nSubstituting the numerical values:\n$$\\Delta C_{\\mathrm{ss}} = 2.0 \\, \\text{mg/dL} - 0.7 \\, \\text{mg/dL} = 1.3 \\, \\text{mg/dL}$$\n\nFinally, the problem requires the answer to be rounded to four significant figures.\n$$\\Delta C_{\\mathrm{ss}} = 1.300 \\, \\text{mg/dL}$$",
            "answer": "$$\\boxed{1.300}$$"
        }
    ]
}